Long-Term Efficacy and Safety Profile of Romiplostim in Patients with Persistent Thrombocytopenia Following Chemotherapy
-
By
-
Andrew B. Song
-
Gerald A. Soff
-
September 28, 2026
Clinical Scorecard: Long-Term Efficacy and Safety Profile of Romiplostim in Patients with Persistent Thrombocytopenia Following Chemotherapy
At a Glance
| Category | Detail |
|---|
| Condition | Persistent Thrombocytopenia Following Chemotherapy |
| Key Mechanisms | Thrombopoietin receptor agonists (TPO-RAs) stimulate platelet production. |
| Target Population | Patients with solid tumors experiencing persistent chemotherapy-induced thrombocytopenia. |
| Care Setting | Oncology |
Key Highlights
- Romiplostim showed a 93% recovery rate in platelet counts compared to 12% in placebo.
- Only 6.8% of patients on romiplostim experienced chemotherapy dose reductions due to CIT.
- TPO-RAs, including romiplostim, are effective in maintaining chemotherapy dose intensity.
- NCCN and ISTH guidelines recommend considering off-label romiplostim for persistent CIT.
Guideline-Based Recommendations
Diagnosis
- Persistent CIT diagnosed after at least 4 weeks of chemotherapy with insufficient platelet recovery.
Management
- Consider off-label use of romiplostim for managing persistent CIT.
Monitoring & Follow-up
- Monitor platelet counts and chemotherapy dose adjustments.
Risks
- Potential for thrombosis, although no increased risk was observed in studies.
Patient & Prescribing Data
Patients with solid tumors and persistent CIT.
Romiplostim is effective in correcting persistent CIT and enabling chemotherapy continuation.
Clinical Best Practices
- Utilize TPO-RAs for patients with persistent CIT to avoid chemotherapy dose reductions.
- Assess platelet counts regularly to guide treatment decisions.
Related Resources & Content
